Roche, Tecentriq, subcutaneous injection, subcutaneous Tecentriq, FDA setback, immunotherapy

Roche’s subcutaneous Tecentriq faces FDA setback due to manufacturing updates

Anika Sharma

Roche may experience a delay in the FDA decision for its subcutaneous version of the cancer immunotherapy Tecentriq, as it ...

Tecentriq, Roche, Lung Cancer, NSCLC, Alecensa, Clinical trial results, ALK-positive NSCLC

Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead

Anika Sharma

With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...

Tecentriq, Roche, Immunotherapy, PD-L1 inhibitor, lung cancer, bladder cancer, breast cancer, liver cancer

Tecentriq SC: A Swift Leap Forward in Cancer Treatment Receives Green Light

Anika Sharma

Roche has proudly unveiled that Tecentriq SC (atezolizumab) has received the stamp of approval from the Medicines and Healthcare products ...

Roche, Lung Cancer, TIGIT, Tecentriq, tiragolumab, Clinical trial results, NSCLC

Roche Unveils Interim TIGIT Overall Survival Data Following Unintended Release, Triggering Surge in Stocks

Anika Sharma

An unexpected revelation has provided the world with a sneak peek into Roche’s highly anticipated TIGIT data. Roche, which had ...

Roche, Exelixis, Ipsen, Cabometyx, Tecentriq, Prostate cancer

Resilient Triumph: Roche and Exelixis’ Tecentriq-Cabometyx Combination Shows Promise in Advanced Prostate Cancer After Past Challenges

Anika Sharma

After facing setbacks in clinical trials, the combination of Roche’s Tecentriq and Exelixis’ Cabometyx has achieved a breakthrough in treating ...